Biotech Start-up Symposium
Event Postponed Until November 2020
Due to the global health concerns, we have made the decision to postpone this event until November, 2020. Further details will be provided as they become available.
Join your colleagues at this two-day symposium and networking event designed specifically for start-up biotech companies. Hosted at Merck in Molsheim, France, speakers will be discussing topics that range from technical (oxygen transfer modelling for bioreactor scaling) to growing your company (going from an idea at a university to a clinical phase biotech) to operations (outsourcing and virtual companies).
This event will include: presentations by industry experts, moderated round table discussions, M Lab™ Collaboration Center tours and exceptional networking opportunities throughout the entire program.
Day 1
| 8:00- 10:00 AM | Breakfast and Registration |
| 10:00 - 10:30 AM | Welcome Frederic Sengler & Ushma Mehta, Merck |
| 10:30 - 11:15 AM | Application of DOE based oxygen transfer modelling to improve bioreactor scale up and scale down Dr Ronan O’Kennedy – ROK Bioconsulting |
| 11:15 - 12:00 AM | Roundtable Discussion |
| 12:00 - 1:00 PM | Lunch at M Lab |
| 1:00 - 1:45 PM | Considerations for the Development of Biologics by Virtual Companies Jonathan Dempsey – Dempsey Consulting |
| 1:45 - 2:30 PM | Roundtable Discussion |
| 2:30 - 3:15 PM | Break and Poster Session |
| 3:15 - 4:00 PM | Faster, safer and affordable access to GMP grade Angiogenic Stem Cell for academic clinical trial Pierre Monsan – Cell-Easy |
| 4:00 - 4:45 PM | Presentation by: 2020 Advance Biotech Grant Recipient |
| 4:45 - 5:45 PM | Transfer to Strasbourg |
| 5:45 – 10:00 PM | Evening event + 2020 Advance Biotech Grant Award Ceremony |
Day 2
| 8:00- 9:00 AM | Transfer from Hotel to M Lab™ Collaboration Center |
| 9:00 – 9:45 AM | TILT’s route from university startup to a clinical stage biotech Aino Kalervo – Tilt Biotherapeutics |
| 9:45 – 10:30 AM | Next Generation Gene Therapy for Musculoskeletal Disorders Kilian Guse - GeneQuine |
| 10:30 – 11:15 AM | Break and Poster Session |
| 11:15 AM – 12:00 PM | Roundtable Discussion |
| 12:00 – 12:45 PM | Financing Strategies for Emerging Biotech Joey Mason- MVentures |
| 12:45 – 1:45 PM | Lunch |
| 1:45 – 2:30 PM |
ImCheck Bring the First gd T Cell Activating Antibody to the Clinic Pierre d’Epenoux – ImCheck Therapeutics |
| 2:30 – 3:15 PM | Ned Wakeman- BioHub Alderley Park |
| 3:15 – 3:30 PM | Closing Session |
Roundtable Discussions:
- Biotech Start-up/CDMO Partner: Setting the right level of expectation to insure project success
- Moderator: Alain Rachon - Director Business Development Merck Biodevelopment
- Process scale up strategies with respect to eventual tech transfer
- Moderator: Dr Paul Beckett – Technology manager, Merck
- Tour our brand new M Lab™ Collaboration Center
European Advance Biotech Grant Program
Program Information
Your promising molecule requires resources and support to realize it’s potential. Our Advance Biotech Grant Program, 9th edition, is open for European* biotech companies, to help you accelerate to clinic faster.
Apply now for a chance to win bioprocessing technologies, bioprocessing process development support, and Active and Formulations technologies.
This year a single grand prize of €240,000 will be awarded in bioprocess technologies, process development support, and actives and formulations. Excludes BioReliance® services.
Please submit a completed application before March 1, 2020. Grant Winner will be announced in April 2020.
- Netherlands, Belgium, Switzerland, United Kingdom, Ireland, France, Germany, Denmark, Finland, Norway, Austria, Spain, Portugal and Sweden – see official rules for eligibility.